Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study

Gene fusions involving NTRK1, NTRK2, or NTRK3 (TRK fusions) are found in a broad range of paediatric and adult malignancies. Larotrectinib, a highly selective small-molecule inhibitor of the TRK kinases, had shown activity in preclinical models and in adults with tumours harbouring TRK fusions. This...

Full description

Saved in:
Bibliographic Details
Published in:The lancet oncology Vol. 19; no. 5; pp. 705 - 714
Main Authors: Laetsch, Theodore W, DuBois, Steven G, Mascarenhas, Leo, Turpin, Brian, Federman, Noah, Albert, Catherine M, Nagasubramanian, Ramamoorthy, Davis, Jessica L, Rudzinski, Erin, Feraco, Angela M, Tuch, Brian B, Ebata, Kevin T, Reynolds, Mark, Smith, Steven, Cruickshank, Scott, Cox, Michael C, Pappo, Alberto S, Hawkins, Douglas S
Format: Journal Article
Language:English
Published: England Elsevier Ltd 01.05.2018
Elsevier Limited
Subjects:
ISSN:1470-2045, 1474-5488, 1474-5488
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first